COEGIN PHARMA AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.88 SEK | +5.00% |
|
+20.99% | +9.19% |
Coegin Pharma AB, formerly GoldBlue AB (publ) is a Sweden-based biotechnology company. The Company focuses on the development of small molecule therapies aimed at the key enzyme, which is known for its involvement in a variety of inflammatory diseases as well as in cancer. Coegin Pharma AB provides consulting and management services in drug development as well.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +9.19% | 9.01M | |
| +45.81% | 56.65B | |
| -7.19% | 39.44B | |
| +39.19% | 39.03B | |
| -6.65% | 26.86B | |
| +12.24% | 26.75B | |
| -21.41% | 19.03B | |
| +0.91% | 12.28B | |
| +23.87% | 12.26B | |
| +27.24% | 12.04B |
- Stock Market
- Equities
- COEGIN Stock
- News Coegin Pharma AB
- Coegin Pharma : Shares Surge 12% On Regulatory Nod For Lead Drug Candidate
